Anton Alexandrovich Lyapin, Irina Nikolaevna Lyapina, Alexandra Alexandrovna Rumiantseva, Roman Sergeevich Tarasov
The purpose: Evaluation of the short-term and long-term results of a phased correction of the tetralogy of Fallot (ToF) with stenting of the right ventricular outflow tract (RVOT) in comparison with a one-stage total correction (TC) of the defect.
Materials and methods: Two groups of patients with classical ToF were formed. Group 1 (n = 25; median age = 72 days) was initially represented by children with ToF with a more severe clinical status (median weight = 3.6 kg, with more pronounced cyanosis and with comorbidities). The children of group 1 underwent the first stage of RVOT stenting and the second stage of TC of ToF. Group 2 (n = 25) was represented by older patients, with a higher body weight and SpO2 level, and they underwent a single-stage TC of the defect.
Results: The application of a step-by-step ToF correction approach with RVOT stenting in low-weight newborns with severe hypoxemia demonstrated an equivalent effect on SpO2 dynamics-reverse remodeling of the heart-when compared with a less severe cohort of patients who underwent simultaneous TC of classical ToF. After RVOT stenting in children from group 1, the median SpO2 increased from 80% to 94.5%, the median Z value of the pulmonary artery trunk decreased from -3.46 mm to -2.54 mm, and the median index of end-diastolic volume of the left ventricle decreased from 23.07 mm/m2 to 57.6 mL/m2. TC of ToF in children from group 1 with a phased strategy of correction of the defect was no less successful than in children who underwent simultaneous TC. In the long-term follow-up period after TC of ToF, children from both groups, who were obviously unequal in their initial status, were practically comparable in clinical characteristics, exhibiting features of cardiac remodeling and achieving endpoints. And there were no significant differences between the two groups in the frequency of reaching the endpoints such as re-operations, cerebrovascular events, and death during the annual, three-year, and five-year follow-up period.
Conclusions: The strategy of RVOT stenting followed by TC of ToF in a severe group of children demonstrated comparable results compared with the results of simultaneous TC of ToF in a more stable group of patients during the in-hospital, annual, three-year, and five-year follow-up periods.
{"title":"Five-Year Comparison Results Between Clinically Severely Affected Tetralogy-of-Fallot Patients Initially Treated by Right Ventricular Outflow Stenting and Pink-Fallot Patients Undergoing Single-Step Correction.","authors":"Anton Alexandrovich Lyapin, Irina Nikolaevna Lyapina, Alexandra Alexandrovna Rumiantseva, Roman Sergeevich Tarasov","doi":"10.3390/jcdd11120398","DOIUrl":"10.3390/jcdd11120398","url":null,"abstract":"<p><strong>The purpose: </strong>Evaluation of the short-term and long-term results of a phased correction of the tetralogy of Fallot (ToF) with stenting of the right ventricular outflow tract (RVOT) in comparison with a one-stage total correction (TC) of the defect.</p><p><strong>Materials and methods: </strong>Two groups of patients with classical ToF were formed. Group 1 (n = 25; median age = 72 days) was initially represented by children with ToF with a more severe clinical status (median weight = 3.6 kg, with more pronounced cyanosis and with comorbidities). The children of group 1 underwent the first stage of RVOT stenting and the second stage of TC of ToF. Group 2 (n = 25) was represented by older patients, with a higher body weight and SpO2 level, and they underwent a single-stage TC of the defect.</p><p><strong>Results: </strong>The application of a step-by-step ToF correction approach with RVOT stenting in low-weight newborns with severe hypoxemia demonstrated an equivalent effect on SpO2 dynamics-reverse remodeling of the heart-when compared with a less severe cohort of patients who underwent simultaneous TC of classical ToF. After RVOT stenting in children from group 1, the median SpO2 increased from 80% to 94.5%, the median Z value of the pulmonary artery trunk decreased from -3.46 mm to -2.54 mm, and the median index of end-diastolic volume of the left ventricle decreased from 23.07 mm/m<sup>2</sup> to 57.6 mL/m<sup>2</sup>. TC of ToF in children from group 1 with a phased strategy of correction of the defect was no less successful than in children who underwent simultaneous TC. In the long-term follow-up period after TC of ToF, children from both groups, who were obviously unequal in their initial status, were practically comparable in clinical characteristics, exhibiting features of cardiac remodeling and achieving endpoints. And there were no significant differences between the two groups in the frequency of reaching the endpoints such as re-operations, cerebrovascular events, and death during the annual, three-year, and five-year follow-up period.</p><p><strong>Conclusions: </strong>The strategy of RVOT stenting followed by TC of ToF in a severe group of children demonstrated comparable results compared with the results of simultaneous TC of ToF in a more stable group of patients during the in-hospital, annual, three-year, and five-year follow-up periods.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
George E Zakynthinos, Ioannis Gialamas, Vasiliki Tsolaki, Panteleimon Pantelidis, Athina Goliopoulou, Maria Ioanna Gounaridi, Ioanna Tzima, Andrew Xanthopoulos, Konstantinos Kalogeras, Gerasimos Siasos, Evangelos Oikonomou
Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder, often complicated by cardiogenic shock, a life-threatening condition marked by severe cardiac output failure. Managing cardiogenic shock in HCM patients presents unique challenges due to the distinct pathophysiology of the disease, which includes dynamic left ventricular outflow tract obstruction, diastolic dysfunction, and myocardial ischemia. This review discusses current and emerging therapeutic strategies tailored to address the complexities of HCM-associated cardiogenic shock and other diseases with similar pathophysiology that provoke left ventricular outflow tract obstruction. We explore the role of pharmacological interventions, including the use of vasopressors and inotropes, which are crucial in stabilizing hemodynamics but require careful selection to avoid exacerbating the outflow obstruction. Additionally, the review highlights advancements in mechanical circulatory support devices such as extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVADs), which have become vital in the acute management of cardiogenic shock. These devices provide temporary support and bridge patients to recovery, definitive therapy, or heart transplantation, which remains a critical option for those with end-stage disease. Furthermore, the review delves into the latest research and clinical trials that are refining these therapeutic approaches, ensuring they are optimized for HCM patients. The impact of these treatments on patient outcomes, including survival rates and quality of life, is also critically assessed. In conclusion, this review underscores the importance of a tailored therapeutic approach in managing cardiogenic shock in HCM patients, integrating pharmacological and mechanical support strategies to improve outcomes in this high-risk population.
{"title":"Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies.","authors":"George E Zakynthinos, Ioannis Gialamas, Vasiliki Tsolaki, Panteleimon Pantelidis, Athina Goliopoulou, Maria Ioanna Gounaridi, Ioanna Tzima, Andrew Xanthopoulos, Konstantinos Kalogeras, Gerasimos Siasos, Evangelos Oikonomou","doi":"10.3390/jcdd11120401","DOIUrl":"10.3390/jcdd11120401","url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder, often complicated by cardiogenic shock, a life-threatening condition marked by severe cardiac output failure. Managing cardiogenic shock in HCM patients presents unique challenges due to the distinct pathophysiology of the disease, which includes dynamic left ventricular outflow tract obstruction, diastolic dysfunction, and myocardial ischemia. This review discusses current and emerging therapeutic strategies tailored to address the complexities of HCM-associated cardiogenic shock and other diseases with similar pathophysiology that provoke left ventricular outflow tract obstruction. We explore the role of pharmacological interventions, including the use of vasopressors and inotropes, which are crucial in stabilizing hemodynamics but require careful selection to avoid exacerbating the outflow obstruction. Additionally, the review highlights advancements in mechanical circulatory support devices such as extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVADs), which have become vital in the acute management of cardiogenic shock. These devices provide temporary support and bridge patients to recovery, definitive therapy, or heart transplantation, which remains a critical option for those with end-stage disease. Furthermore, the review delves into the latest research and clinical trials that are refining these therapeutic approaches, ensuring they are optimized for HCM patients. The impact of these treatments on patient outcomes, including survival rates and quality of life, is also critically assessed. In conclusion, this review underscores the importance of a tailored therapeutic approach in managing cardiogenic shock in HCM patients, integrating pharmacological and mechanical support strategies to improve outcomes in this high-risk population.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ivo Deblier, Karl Dossche, Anthony Vanermen, Wilhelm Mistiaen
The need for a permanent pacemaker (PPM) implantation after surgical aortic valve implantation (SAVR) is a recognized postoperative complication, with potentially long-term reduced survival. From 1987 to 2017, 2500 consecutive patients underwent SAVR with a biological valve with or without concomitant procedures such as CABG or mitral valve repair. Mechanical valves or valves in another position were excluded. Univariate and multivariate analyses were performed. The need for PPM implantation was documented in 2.7% of the cases. Patients with a postoperative PPM were older and had higher risk scores and a higher comorbid burden. Its predictors were a prior SAVR (odds ratio of 5.38, p < 0.001), use of a Perceval valve (3.94, p = 0.008), prior AV block 1-2 (2.86, p = 0.008), and pulmonary hypertension (2.09, p = 0.017). The need for PPM implantation was associated with an increased need for blood products, a prolonged stay in the ICU, and an increased 30-day mortality (2.5% vs. 7.0%, p = 0.005). The median survival decreased from 117 (114-120) to 90 (74-105) months (p < 0.001). The implantation had no significant effect on the freedom of congestive heart failure. The need for a PPM implant is not a benign event but might be a marker for a more severe underlying disease. Improving surgical techniques, especially with the Perceval rapid deployment valve, might decrease the need for a PPM implant.
{"title":"Predictors of the Need for Permanent Pacemaker Implantation After Surgical Aortic Valve Replacement with a Biological Prosthesis and the Effect on Long-Term Survival.","authors":"Ivo Deblier, Karl Dossche, Anthony Vanermen, Wilhelm Mistiaen","doi":"10.3390/jcdd11120397","DOIUrl":"10.3390/jcdd11120397","url":null,"abstract":"<p><p>The need for a permanent pacemaker (PPM) implantation after surgical aortic valve implantation (SAVR) is a recognized postoperative complication, with potentially long-term reduced survival. From 1987 to 2017, 2500 consecutive patients underwent SAVR with a biological valve with or without concomitant procedures such as CABG or mitral valve repair. Mechanical valves or valves in another position were excluded. Univariate and multivariate analyses were performed. The need for PPM implantation was documented in 2.7% of the cases. Patients with a postoperative PPM were older and had higher risk scores and a higher comorbid burden. Its predictors were a prior SAVR (odds ratio of 5.38, <i>p</i> < 0.001), use of a Perceval valve (3.94, <i>p</i> = 0.008), prior AV block 1-2 (2.86, <i>p</i> = 0.008), and pulmonary hypertension (2.09, <i>p</i> = 0.017). The need for PPM implantation was associated with an increased need for blood products, a prolonged stay in the ICU, and an increased 30-day mortality (2.5% vs. 7.0%, <i>p</i> = 0.005). The median survival decreased from 117 (114-120) to 90 (74-105) months (<i>p</i> < 0.001). The implantation had no significant effect on the freedom of congestive heart failure. The need for a PPM implant is not a benign event but might be a marker for a more severe underlying disease. Improving surgical techniques, especially with the Perceval rapid deployment valve, might decrease the need for a PPM implant.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Cardiac computed tomography (CT) helps screen coronary artery stenosis in cases with dilated cardiomyopathy (DCM). Extracellular volume fraction (ECV) analysis has recently been eligible for CT.
Method: We evaluated the impact of ECV on the CT to predict the prognosis in DCM patients with heart failure with reduced ejection fraction (HFrEF).
Patients or materials: We analyzed 101 consecutive DCM cases with HFrEF who underwent cardiac CT. All the patients had a lower left ventricular (LV) ejection fraction (LVEF) of less than 40%. We evaluated the effect of ECV to predict the patients' prognosis. Cardiovascular death, hospitalization due to heart failure, and fatal arrhythmic events were included in the major adverse cardiac events (MACE).
Results: MACE occurred in 27 cases (27%). The patients with MACE (27 cases) had an increased ECV on the LVM on the CT (37.2 ± 6.7 vs. 32.2 ± 3.6%, p = 0.0008) compared to the others (74 cases). Based on the receiver operating characteristics curve analysis, the best cutoff value of the ECV on the LVM to predict the MACE was 32.3%. The patients with ECV ≥ 32.3% had significantly higher MACE based on the Kaplan-Meier analysis. The ECV on the LVM was a significant marker to predict MACE based on the univariate Cox proportional hazard model (hazard ratio of 8.00, 95% confidence interval 1.88-33.97, p = 0.0048).
Conclusions: ECV by CT is helpful to predict MACE in cases with DCM and HFrEF.
{"title":"Extracellular Volume by Computed Tomography Is Useful for Prediction of Prognosis in Dilated Cardiomyopathy Cases with Heart Failure with Reduced Ejection Fraction.","authors":"Satomi Yashima, Hiroyuki Takaoka, Joji Ota, Moe Matsumoto, Yusei Nishikawa, Yoshitada Noguchi, Shuhei Aoki, Kazuki Yoshida, Katsuya Suzuki, Makiko Kinoshita, Haruka Sasaki, Noriko Suzuki-Eguchi, Tomonori Kanaeda, Yoshio Kobayashi","doi":"10.3390/jcdd11120399","DOIUrl":"10.3390/jcdd11120399","url":null,"abstract":"<p><strong>Objective: </strong>Cardiac computed tomography (CT) helps screen coronary artery stenosis in cases with dilated cardiomyopathy (DCM). Extracellular volume fraction (ECV) analysis has recently been eligible for CT.</p><p><strong>Method: </strong>We evaluated the impact of ECV on the CT to predict the prognosis in DCM patients with heart failure with reduced ejection fraction (HFrEF).</p><p><strong>Patients or materials: </strong>We analyzed 101 consecutive DCM cases with HFrEF who underwent cardiac CT. All the patients had a lower left ventricular (LV) ejection fraction (LVEF) of less than 40%. We evaluated the effect of ECV to predict the patients' prognosis. Cardiovascular death, hospitalization due to heart failure, and fatal arrhythmic events were included in the major adverse cardiac events (MACE).</p><p><strong>Results: </strong>MACE occurred in 27 cases (27%). The patients with MACE (27 cases) had an increased ECV on the LVM on the CT (37.2 ± 6.7 vs. 32.2 ± 3.6%, <i>p</i> = 0.0008) compared to the others (74 cases). Based on the receiver operating characteristics curve analysis, the best cutoff value of the ECV on the LVM to predict the MACE was 32.3%. The patients with ECV ≥ 32.3% had significantly higher MACE based on the Kaplan-Meier analysis. The ECV on the LVM was a significant marker to predict MACE based on the univariate Cox proportional hazard model (hazard ratio of 8.00, 95% confidence interval 1.88-33.97, <i>p</i> = 0.0048).</p><p><strong>Conclusions: </strong>ECV by CT is helpful to predict MACE in cases with DCM and HFrEF.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paul Iacobescu, Virginia Marina, Catalin Anghel, Aurelian-Dumitrache Anghele
Cardiovascular disease (CVD) is a significant global health concern and the leading cause of death in many countries. Early detection and diagnosis of CVD can significantly reduce the risk of complications and mortality. Machine learning methods, particularly classification algorithms, have demonstrated their potential to accurately predict the risk of cardiovascular disease (CVD) by analyzing patient data. This study evaluates seven binary classification algorithms, including Random Forests, Logistic Regression, Naive Bayes, K-Nearest Neighbors (kNN), Support Vector Machines, Gradient Boosting, and Artificial Neural Networks, to understand their effectiveness in predicting CVD. Advanced preprocessing techniques, such as SMOTE-ENN for addressing class imbalance and hyperparameter optimization through Grid Search Cross-Validation, were applied to enhance the reliability and performance of these models. Standard evaluation metrics, including accuracy, precision, recall, F1-score, and Area Under the Receiver Operating Characteristic Curve (ROC-AUC), were used to assess predictive capabilities. The results show that kNN achieved the highest accuracy (99%) and AUC (0.99), surpassing traditional models like Logistic Regression and Gradient Boosting. The study examines the challenges encountered when working with datasets related to cardiovascular diseases, such as class imbalance and feature selection. It demonstrates how addressing these issues enhances the reliability and applicability of predictive models. These findings emphasize the potential of kNN as a reliable tool for early CVD prediction, offering significant improvements over previous studies. This research highlights the value of advanced machine learning techniques in healthcare, addressing key challenges and laying a foundation for future studies aimed at improving predictive models for CVD prevention.
{"title":"Evaluating Binary Classifiers for Cardiovascular Disease Prediction: Enhancing Early Diagnostic Capabilities.","authors":"Paul Iacobescu, Virginia Marina, Catalin Anghel, Aurelian-Dumitrache Anghele","doi":"10.3390/jcdd11120396","DOIUrl":"10.3390/jcdd11120396","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) is a significant global health concern and the leading cause of death in many countries. Early detection and diagnosis of CVD can significantly reduce the risk of complications and mortality. Machine learning methods, particularly classification algorithms, have demonstrated their potential to accurately predict the risk of cardiovascular disease (CVD) by analyzing patient data. This study evaluates seven binary classification algorithms, including Random Forests, Logistic Regression, Naive Bayes, K-Nearest Neighbors (kNN), Support Vector Machines, Gradient Boosting, and Artificial Neural Networks, to understand their effectiveness in predicting CVD. Advanced preprocessing techniques, such as SMOTE-ENN for addressing class imbalance and hyperparameter optimization through Grid Search Cross-Validation, were applied to enhance the reliability and performance of these models. Standard evaluation metrics, including accuracy, precision, recall, F1-score, and Area Under the Receiver Operating Characteristic Curve (ROC-AUC), were used to assess predictive capabilities. The results show that kNN achieved the highest accuracy (99%) and AUC (0.99), surpassing traditional models like Logistic Regression and Gradient Boosting. The study examines the challenges encountered when working with datasets related to cardiovascular diseases, such as class imbalance and feature selection. It demonstrates how addressing these issues enhances the reliability and applicability of predictive models. These findings emphasize the potential of kNN as a reliable tool for early CVD prediction, offering significant improvements over previous studies. This research highlights the value of advanced machine learning techniques in healthcare, addressing key challenges and laying a foundation for future studies aimed at improving predictive models for CVD prevention.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fabrice F Darche, Karsten M Heil, Rasmus Rivinius, Matthias Helmschrott, Philipp Ehlermann, Norbert Frey, Ann-Kathrin Rahm
Aims: Patients after heart transplantation (HTX) often experience post-transplant bradycardia, but little is known about the outcomes of early pacemaker dependency after HTX. We compared post-transplant mortality, graft failure, and the requirement for the permanent pacemaker implantation of patients with and without early pacemaker dependency after HTX.
Methods: We screened all adult patients for early pacemaker dependency after HTX (defined as immediately after surgery) who underwent HTX at Heidelberg Heart Center between 1989 and 2022. Patients were stratified by diagnosis and type of early pacemaker dependency after HTX (sinoatrial or atrioventricular conduction disturbance).
Results: A total of 127 of 699 HTX recipients (18.2%) had early pacemaker dependency after HTX, including 52 patients with sinoatrial conduction disturbances (40.9%) and 75 patients with atrioventricular conduction disturbances (59.1%). Patients with early pacemaker dependency after HTX showed both increased 1-year overall mortality after HTX (55.9% vs. 15.2%, p < 0.001) and higher mortality due to graft failure (25.2% vs. 4.2%, p < 0.001). Multivariate analysis revealed early pacemaker dependency after HTX (HR: 5.226, 95% CI: 3.738-7.304, p < 0.001) as an independent risk factor for 1-year mortality after HTX. Patients with early pacemaker dependency after HTX had a higher rate of 30-day (7.1% vs. 0.4%, p < 0.001) and 1-year (11.8% vs. 0.5%, p < 0.001) permanent pacemaker implantation after HTX compared to patients without early pacemaker dependency after HTX.
Conclusions: Patients with early pacemaker dependency after HTX had a significantly higher rate of post-transplant mortality, graft failure, and the requirement for permanent pacemaker implantation.
目的:心脏移植术后患者经常出现移植后心动过缓,但对心脏移植术后早期起搏器依赖的结果知之甚少。我们比较了HTX术后早期和非早期起搏器依赖患者的移植后死亡率、移植失败和永久起搏器植入需求。方法:我们筛选了1989年至2022年间在海德堡心脏中心接受HTX手术的所有成年患者在HTX术后早期起搏器依赖(定义为术后立即)。根据HTX(窦房或房室传导障碍)后早期起搏器依赖的诊断和类型对患者进行分层。结果:699例HTX受者中127例(18.2%)出现HTX术后早期起搏器依赖,其中窦房传导障碍52例(40.9%),房室传导障碍75例(59.1%)。HTX术后早期起搏器依赖患者显示HTX术后1年总死亡率增加(55.9% vs. 15.2%, p < 0.001),移植物衰竭死亡率增加(25.2% vs. 4.2%, p < 0.001)。多因素分析显示,HTX术后早期起搏器依赖(HR: 5.226, 95% CI: 3.738-7.304, p < 0.001)是HTX术后1年死亡率的独立危险因素。HTX术后早期起搏器依赖患者的30天永久性起搏器植入率(7.1% vs. 0.4%, p < 0.001)和1年永久性起搏器植入率(11.8% vs. 0.5%, p < 0.001)均高于HTX术后无早期起搏器依赖患者。结论:HTX术后早期起搏器依赖患者的移植后死亡率、移植物失败率和永久植入起搏器的需求明显高于其他患者。
{"title":"Early Pacemaker Dependency After Heart Transplantation Is Associated with Permanent Pacemaker Implantation, Graft Failure and Mortality.","authors":"Fabrice F Darche, Karsten M Heil, Rasmus Rivinius, Matthias Helmschrott, Philipp Ehlermann, Norbert Frey, Ann-Kathrin Rahm","doi":"10.3390/jcdd11120394","DOIUrl":"10.3390/jcdd11120394","url":null,"abstract":"<p><strong>Aims: </strong>Patients after heart transplantation (HTX) often experience post-transplant bradycardia, but little is known about the outcomes of early pacemaker dependency after HTX. We compared post-transplant mortality, graft failure, and the requirement for the permanent pacemaker implantation of patients with and without early pacemaker dependency after HTX.</p><p><strong>Methods: </strong>We screened all adult patients for early pacemaker dependency after HTX (defined as immediately after surgery) who underwent HTX at Heidelberg Heart Center between 1989 and 2022. Patients were stratified by diagnosis and type of early pacemaker dependency after HTX (sinoatrial or atrioventricular conduction disturbance).</p><p><strong>Results: </strong>A total of 127 of 699 HTX recipients (18.2%) had early pacemaker dependency after HTX, including 52 patients with sinoatrial conduction disturbances (40.9%) and 75 patients with atrioventricular conduction disturbances (59.1%). Patients with early pacemaker dependency after HTX showed both increased 1-year overall mortality after HTX (55.9% vs. 15.2%, <i>p</i> < 0.001) and higher mortality due to graft failure (25.2% vs. 4.2%, <i>p</i> < 0.001). Multivariate analysis revealed early pacemaker dependency after HTX (HR: 5.226, 95% CI: 3.738-7.304, <i>p</i> < 0.001) as an independent risk factor for 1-year mortality after HTX. Patients with early pacemaker dependency after HTX had a higher rate of 30-day (7.1% vs. 0.4%, <i>p</i> < 0.001) and 1-year (11.8% vs. 0.5%, <i>p</i> < 0.001) permanent pacemaker implantation after HTX compared to patients without early pacemaker dependency after HTX.</p><p><strong>Conclusions: </strong>Patients with early pacemaker dependency after HTX had a significantly higher rate of post-transplant mortality, graft failure, and the requirement for permanent pacemaker implantation.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11679924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liam Butler, Alexander Ivanov, Turgay Celik, Ibrahim Karabayir, Lokesh Chinthala, Mohammad S Tootooni, Byron C Jaeger, Luke T Patterson, Adam J Doerr, David D McManus, Robert L Davis, David Herrington, Oguz Akbilgic
Background: Fatal coronary heart disease (FCHD) affects ~650,000 people yearly in the US. Electrocardiographic artificial intelligence (ECG-AI) models can predict adverse coronary events, yet their application to FCHD is understudied. Objectives: The study aimed to develop ECG-AI models predicting FCHD risk from ECGs. Methods (Retrospective): Data from 10 s 12-lead ECGs and demographic/clinical data from University of Tennessee Health Science Center (UTHSC) were used for model development. Of this dataset, 80% was used for training and 20% as holdout. Data from Atrium Health Wake Forest Baptist (AHWFB) were used for external validation. We developed two separate convolutional neural network models using 12-lead and Lead I ECGs as inputs, and time-dependent Cox proportional hazard models using demographic/clinical data with ECG-AI outputs. Correlation of the predictions from the 12- and 1-lead ECG-AI models was assessed. Results: The UTHSC cohort included data from 50,132 patients with a mean age (SD) of 62.50 (14.80) years, of whom 53.4% were males and 48.5% African American. The AHWFB cohort included data from 2305 patients with a mean age (SD) of 63.04 (16.89) years, of whom 51.0% were males and 18.8% African American. The 12-lead and Lead I ECG-AI models resulted in validation AUCs of 0.84 and 0.85, respectively. The best overall model was the Cox model using simple demographics with Lead I ECG-AI output (D1-ECG-AI-Cox), with the following results: AUC = 0.87 (0.85-0.89), accuracy = 83%, sensitivity = 69%, specificity = 89%, negative predicted value (NPV) = 92% and positive predicted value (PPV) = 55% on the AHWFB validation cohort. For this, the 2-year FCHD risk prediction accuracy was AUC = 0.91 (0.90-0.92). The 12-lead versus Lead I ECG FCHD risk prediction showed strong correlation (R = 0.74). Conclusions: The 2-year FCHD risk can be predicted with high accuracy from single-lead ECGs, further improving when combined with demographic information.
背景:致死性冠心病(FCHD)在美国每年影响约65万人。心电图人工智能(ECG-AI)模型可以预测不良冠状动脉事件,但其在FCHD中的应用尚未得到充分研究。目的:本研究旨在建立通过心电图预测FCHD风险的ECG-AI模型。方法(回顾性):采用10年12导联心电图数据和田纳西大学健康科学中心(UTHSC)的人口统计学/临床数据进行模型开发。在这个数据集中,80%用于训练,20%用于保留。来自Atrium Health Wake Forest Baptist (AHWFB)的数据用于外部验证。我们开发了两个独立的卷积神经网络模型,使用12导联和1导联心电图作为输入,以及使用人口统计学/临床数据和ECG-AI输出的时间相关Cox比例风险模型。评估12导联和1导联ECG-AI模型预测的相关性。结果:UTHSC队列纳入了50,132例患者的数据,平均年龄(SD)为62.50(14.80)岁,其中53.4%为男性,48.5%为非洲裔美国人。AHWFB队列包括2305例患者的数据,平均年龄(SD)为63.04(16.89)岁,其中51.0%为男性,18.8%为非洲裔美国人。12导联和1导联ECG-AI模型的验证auc分别为0.84和0.85。最佳的综合模型是使用铅I ECG-AI输出(D1-ECG-AI-Cox)的简单人口统计学Cox模型,其结果如下:AHWFB验证队列的AUC = 0.87(0.85-0.89),准确性= 83%,灵敏度= 69%,特异性= 89%,阴性预测值(NPV) = 92%,阳性预测值(PPV) = 55%。因此,2年FCHD风险预测准确率AUC = 0.91(0.90-0.92)。12导联与1导联心电图FCHD风险预测相关性强(R = 0.74)。结论:单导联心电图可准确预测2年FCHD风险,结合人口统计学信息可进一步提高预测准确率。
{"title":"Time-Dependent ECG-AI Prediction of Fatal Coronary Heart Disease: A Retrospective Study.","authors":"Liam Butler, Alexander Ivanov, Turgay Celik, Ibrahim Karabayir, Lokesh Chinthala, Mohammad S Tootooni, Byron C Jaeger, Luke T Patterson, Adam J Doerr, David D McManus, Robert L Davis, David Herrington, Oguz Akbilgic","doi":"10.3390/jcdd11120395","DOIUrl":"10.3390/jcdd11120395","url":null,"abstract":"<p><p><b>Background</b>: Fatal coronary heart disease (FCHD) affects ~650,000 people yearly in the US. Electrocardiographic artificial intelligence (ECG-AI) models can predict adverse coronary events, yet their application to FCHD is understudied. <b>Objectives</b>: The study aimed to develop ECG-AI models predicting FCHD risk from ECGs. <b>Methods (Retrospective)</b>: Data from 10 s 12-lead ECGs and demographic/clinical data from University of Tennessee Health Science Center (UTHSC) were used for model development. Of this dataset, 80% was used for training and 20% as holdout. Data from Atrium Health Wake Forest Baptist (AHWFB) were used for external validation. We developed two separate convolutional neural network models using 12-lead and Lead I ECGs as inputs, and time-dependent Cox proportional hazard models using demographic/clinical data with ECG-AI outputs. Correlation of the predictions from the 12- and 1-lead ECG-AI models was assessed. <b>Results</b>: The UTHSC cohort included data from 50,132 patients with a mean age (SD) of 62.50 (14.80) years, of whom 53.4% were males and 48.5% African American. The AHWFB cohort included data from 2305 patients with a mean age (SD) of 63.04 (16.89) years, of whom 51.0% were males and 18.8% African American. The 12-lead and Lead I ECG-AI models resulted in validation AUCs of 0.84 and 0.85, respectively. The best overall model was the Cox model using simple demographics with Lead I ECG-AI output (D1-ECG-AI-Cox), with the following results: AUC = 0.87 (0.85-0.89), accuracy = 83%, sensitivity = 69%, specificity = 89%, negative predicted value (NPV) = 92% and positive predicted value (PPV) = 55% on the AHWFB validation cohort. For this, the 2-year FCHD risk prediction accuracy was AUC = 0.91 (0.90-0.92). The 12-lead versus Lead I ECG FCHD risk prediction showed strong correlation (R = 0.74). <b>Conclusions</b>: The 2-year FCHD risk can be predicted with high accuracy from single-lead ECGs, further improving when combined with demographic information.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pediatric patients supported by extracorporeal ventricular assist devices traditionally require long-term stationary inpatient settings. Limited mobility and permanent hospitalization significantly reduce their quality of life. Berlin Heart address this with their novel mobile driving unit, EXCOR® Active. This case report presents its first application outside of Germany, where it was developed, focusing on staff education and safety measures leading to a successful switch of driving units.
{"title":"The Introduction of a New Mobile Driving Unit for a Ventricular Assist Device in a Pediatric Patient (EXCOR Active).","authors":"Nuri Ünesen, Christian Balmer, Martin Schweiger","doi":"10.3390/jcdd11120392","DOIUrl":"10.3390/jcdd11120392","url":null,"abstract":"<p><p>Pediatric patients supported by extracorporeal ventricular assist devices traditionally require long-term stationary inpatient settings. Limited mobility and permanent hospitalization significantly reduce their quality of life. Berlin Heart address this with their novel mobile driving unit, EXCOR<sup>®</sup> Active. This case report presents its first application outside of Germany, where it was developed, focusing on staff education and safety measures leading to a successful switch of driving units.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11677815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stasa Krasic, Sofija Popovic, Vesna Topic, Mila Stajevic, Ivan Dizdarevic, Sasa Popovic, Dejan Nesic, Vladislav Vukomanovic
Background: The vertical vein (VV) ligation during the total anomalous pulmonary venous return (TAPVR) correction is still controversial. Our study aimed to define the potential risk factors for VV persistence and their percutaneous occlusion.
Methods: The retrospective cohort study included 40 patients (26 males) with TAPVR treated at the tertiary referral center from 2005 to 2024.
Results: The average days of age at diagnosis was two (IQR 1-8). Complex congenital heart disease with TAPVR was diagnosed in eight patients. A supracardiac type of TAPVR was found in 47% of them. The patients underwent the operation on their eighth day of life (IQR 5-57). The follow-up period was 32 months (IQR 8-99). The early postoperative mortality rate was 17.5%, significantly frequent in the patients' group with combined CHD (p = 0.002). Four were reoperated on-three due to a postoperative obstruction between the pulmonary venous confluence and the left atrium (LA), while in one patient, a redirection of the VCI was performed. Four patients, aged 12.3 on average (IQR 8.9-14.7), underwent vertical vein embolization. All patients achieved complete occlusion with AVP2. The LA diameter Z score was lower than -4, an increased risk for VV persistence of almost 19 times (OR 18.6, 95% CI 1.6-216.0).
Conclusions: We found that an LA diameter Z score of lower than -4 was a major risk factor for VV persistence. Percutaneous VV embolization is a safe and effective procedure in adolescents.
{"title":"Percutaneous Embolization of No Ligated Vertical Veins After Total Anomalous Pulmonary Vein Return Operation and Risk Factors for Its Persistence.","authors":"Stasa Krasic, Sofija Popovic, Vesna Topic, Mila Stajevic, Ivan Dizdarevic, Sasa Popovic, Dejan Nesic, Vladislav Vukomanovic","doi":"10.3390/jcdd11120393","DOIUrl":"10.3390/jcdd11120393","url":null,"abstract":"<p><strong>Background: </strong>The vertical vein (VV) ligation during the total anomalous pulmonary venous return (TAPVR) correction is still controversial. Our study aimed to define the potential risk factors for VV persistence and their percutaneous occlusion.</p><p><strong>Methods: </strong>The retrospective cohort study included 40 patients (26 males) with TAPVR treated at the tertiary referral center from 2005 to 2024.</p><p><strong>Results: </strong>The average days of age at diagnosis was two (IQR 1-8). Complex congenital heart disease with TAPVR was diagnosed in eight patients. A supracardiac type of TAPVR was found in 47% of them. The patients underwent the operation on their eighth day of life (IQR 5-57). The follow-up period was 32 months (IQR 8-99). The early postoperative mortality rate was 17.5%, significantly frequent in the patients' group with combined CHD (<i>p</i> = 0.002). Four were reoperated on-three due to a postoperative obstruction between the pulmonary venous confluence and the left atrium (LA), while in one patient, a redirection of the VCI was performed. Four patients, aged 12.3 on average (IQR 8.9-14.7), underwent vertical vein embolization. All patients achieved complete occlusion with AVP2. The LA diameter Z score was lower than -4, an increased risk for VV persistence of almost 19 times (OR 18.6, 95% CI 1.6-216.0).</p><p><strong>Conclusions: </strong>We found that an LA diameter Z score of lower than -4 was a major risk factor for VV persistence. Percutaneous VV embolization is a safe and effective procedure in adolescents.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bethany L Armentrout, Bootan H Ahmed, Sineenat Waraphok, Johnathan Huynh, Stephanie Griggs
Type 1 diabetes (T1D) is a complex chronic condition that places young adults aged 18-31 years at high risk for general and diabetes-related distress and poor cardiovascular health. Both general and diabetes distress are linked to higher A1C, a known risk factor for cardiovascular disease (CVD). The purpose of this cross-sectional quantitative descriptive study was to examine the associations between distress symptoms (general and diabetes) and cardiovascular health while considering covariates in young adults ages 18-31 years with T1D. One-hundred and sixty-five young adults with T1D, recruited from specialty clinics through two major health systems and online platforms, completed a demographic and clinical survey along with the 8-item PROMIS Emotional Distress Scale and 17-item Diabetes Distress Scale. Higher diabetes distress and higher general emotional distress were associated with lower cardiovascular health scores. Associations remained statistically significant after adjusting for age, T1D duration, sex at birth, race, and continuous subcutaneous insulin infusion. In young adults with type 1 diabetes, addressing both diabetes and general emotional distress may be important to improve cardiovascular health. However, longitudinal and experimental studies are needed to clarify underlying mechanisms and evaluate the effectiveness of interventions like cognitive behavioral therapy.
{"title":"Emotional Distress and Cardiovascular Health in Young Adults with Type 1 Diabetes.","authors":"Bethany L Armentrout, Bootan H Ahmed, Sineenat Waraphok, Johnathan Huynh, Stephanie Griggs","doi":"10.3390/jcdd11120391","DOIUrl":"10.3390/jcdd11120391","url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is a complex chronic condition that places young adults aged 18-31 years at high risk for general and diabetes-related distress and poor cardiovascular health. Both general and diabetes distress are linked to higher A1C, a known risk factor for cardiovascular disease (CVD). The purpose of this cross-sectional quantitative descriptive study was to examine the associations between distress symptoms (general and diabetes) and cardiovascular health while considering covariates in young adults ages 18-31 years with T1D. One-hundred and sixty-five young adults with T1D, recruited from specialty clinics through two major health systems and online platforms, completed a demographic and clinical survey along with the 8-item PROMIS Emotional Distress Scale and 17-item Diabetes Distress Scale. Higher diabetes distress and higher general emotional distress were associated with lower cardiovascular health scores. Associations remained statistically significant after adjusting for age, T1D duration, sex at birth, race, and continuous subcutaneous insulin infusion. In young adults with type 1 diabetes, addressing both diabetes and general emotional distress may be important to improve cardiovascular health. However, longitudinal and experimental studies are needed to clarify underlying mechanisms and evaluate the effectiveness of interventions like cognitive behavioral therapy.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 12","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}